189 related articles for article (PubMed ID: 36239754)
1. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.
Martinez-Naharro A; Patel R; Kotecha T; Karia N; Ioannou A; Petrie A; Chacko LA; Razvi Y; Ravichandran S; Brown J; Law S; Quarta C; Mahmood S; Wisniowski B; Pica S; Sachchithanantham S; Lachmann HJ; Moon JC; Knight DS; Whelan C; Venneri L; Xue H; Kellman P; Gillmore JD; Hawkins PN; Wechalekar AD; Fontana M
Eur Heart J; 2022 Dec; 43(45):4722-4735. PubMed ID: 36239754
[TBL] [Abstract][Full Text] [Related]
2. Tracking Multiorgan Treatment Response in Systemic AL-Amyloidosis With Cardiac Magnetic Resonance Derived Extracellular Volume Mapping.
Ioannou A; Patel RK; Martinez-Naharro A; Razvi Y; Porcari A; Hutt DF; Bandera F; Kotecha T; Venneri L; Chacko L; Massa P; Hanger M; Knight D; Manisty C; Moon J; Quarta C; Lachmann H; Whelan C; Kellman P; Hawkins PN; Gillmore JD; Wechelakar A; Fontana M
JACC Cardiovasc Imaging; 2023 Aug; 16(8):1038-1052. PubMed ID: 37178079
[TBL] [Abstract][Full Text] [Related]
3. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis.
Lin L; Li X; Feng J; Shen KN; Tian Z; Sun J; Mao YY; Cao J; Jin ZY; Li J; Selvanayagam JB; Wang YN
J Cardiovasc Magn Reson; 2018 Jan; 20(1):2. PubMed ID: 29298704
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of native T1 and extracellular volume in patients with immunoglubin light-chain amyloidosis.
Liu Y; Wang L; Zhu J; Chen M; Zhu M; Dai Y; Hu C
BMC Cardiovasc Disord; 2024 Feb; 24(1):112. PubMed ID: 38365569
[TBL] [Abstract][Full Text] [Related]
6. T1 mapping and survival in systemic light-chain amyloidosis.
Banypersad SM; Fontana M; Maestrini V; Sado DM; Captur G; Petrie A; Piechnik SK; Whelan CJ; Herrey AS; Gillmore JD; Lachmann HJ; Wechalekar AD; Hawkins PN; Moon JC
Eur Heart J; 2015 Jan; 36(4):244-51. PubMed ID: 25411195
[TBL] [Abstract][Full Text] [Related]
7. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.
Banypersad SM; Sado DM; Flett AS; Gibbs SD; Pinney JH; Maestrini V; Cox AT; Fontana M; Whelan CJ; Wechalekar AD; Hawkins PN; Moon JC
Circ Cardiovasc Imaging; 2013 Jan; 6(1):34-9. PubMed ID: 23192846
[TBL] [Abstract][Full Text] [Related]
8. Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?
Cuddy SAM; Bravo PE; Falk RH; El-Sady S; Kijewski MF; Park MA; Ruberg FL; Sanchorawala V; Landau H; Yee AJ; Bianchi G; Di Carli MF; Cheng SC; Jerosch-Herold M; Kwong RY; Liao R; Dorbala S
JACC Cardiovasc Imaging; 2020 Jun; 13(6):1325-1336. PubMed ID: 32417333
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.
Knight DS; Zumbo G; Barcella W; Steeden JA; Muthurangu V; Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Kotecha T; Francis R; Rezk T; Quarta CC; Whelan CJ; Lachmann HJ; Wechalekar AD; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):823-833. PubMed ID: 29680336
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
[TBL] [Abstract][Full Text] [Related]
11. Light-Chain Cardiac Amyloidosis: Cardiac Magnetic Resonance for Assessing Response to Chemotherapy.
Guo Y; Li X; Gao Y; Shen K; Lin L; Wang J; Cao J; Zhang Z; Wan K; Zhou XY; Chen Y; Zhang LJ; Li J; Wang Y
Korean J Radiol; 2024 May; 25(5):426-437. PubMed ID: 38685733
[TBL] [Abstract][Full Text] [Related]
12. Myocardial structural and functional changes in cardiac amyloidosis: insights from a prospective observational patient registry.
Duca F; Rettl R; Kronberger C; Binder C; Mann C; Dusik F; Schrutka L; Dalos D; Öztürk B; Dachs TM; Cherouny B; Camuz Ligios L; Agis H; Kain R; Koschutnik M; Donà C; Badr-Eslam R; Kastner J; Beitzke D; Loewe C; Nitsche C; Hengstenberg C; Kammerlander AA; Bonderman D
Eur Heart J Cardiovasc Imaging; 2023 Dec; 25(1):95-104. PubMed ID: 37549339
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis.
Briasoulis A; Lama N; Rempakos A; Theodorakakou F; Stamatelopoulos K; Dimopoulos MA; Kelekis N; Kastritis E
Curr Probl Cardiol; 2023 Apr; 48(4):101573. PubMed ID: 36586704
[TBL] [Abstract][Full Text] [Related]
14. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
15. Extracellular Volume Associates With Outcomes More Strongly Than Native or Post-Contrast Myocardial T1.
Treibel TA; Fridman Y; Bering P; Sayeed A; Maanja M; Frojdh F; Niklasson L; Olausson E; Wong TC; Kellman P; Miller CA; Moon JC; Ugander M; Schelbert EB
JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 1):44-54. PubMed ID: 31103587
[TBL] [Abstract][Full Text] [Related]
16. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
Barison A; Aquaro GD; Pugliese NR; Cappelli F; Chiappino S; Vergaro G; Mirizzi G; Todiere G; Passino C; Masci PG; Perfetto F; Emdin M
J Intern Med; 2015 May; 277(5):605-14. PubMed ID: 25346163
[TBL] [Abstract][Full Text] [Related]
17. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study.
Wan K; Li W; Sun J; Xu Y; Wang J; Liu H; Dong Y; Cheng W; Zhang Q; Zeng Z; Zhou X; Han Y; Chen Y
Amyloid; 2019 Mar; 26(1):45-51. PubMed ID: 30931628
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Hepatic T1-Mapping and Extracellular Volume Quantification on Routine Cardiac Magnetic Resonance Imaging in Patients with Infiltrative and Systemic Disorders.
Dolan RS; Stillman AE; Davarpanah AH
Acad Radiol; 2022 Apr; 29 Suppl 4():S100-S109. PubMed ID: 34702675
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric cardiovascular magnetic resonance characteristics and dynamic changes in myocardial and skeletal muscles in idiopathic inflammatory cardiomyopathy.
Xu Y; Sun J; Wan K; Yu L; Wang J; Li W; Yang F; Sun J; Cheng W; Mui D; Zhang Q; Xie Q; Chen Y
J Cardiovasc Magn Reson; 2020 Apr; 22(1):22. PubMed ID: 32272936
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.
Yue X; Yang L; Wang R; Chan Q; Yang Y; Wu X; Ruan X; Zhang Z; Wei Y; Wang F
Front Cardiovasc Med; 2022; 9():1017097. PubMed ID: 36330005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
